Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome

Michael Camilleri, Jan F. Tack

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Dyspepsia is a highly prevalent condition characterized by symptoms originating in the gastroduodenal region without underlying organic disorder. Treatment modalities include acid-suppressive drugs, gastroprokinetic drugs, Helicobacter pylori eradication therapy, tricyclic antidepressants, and psychological therapies. Irritable bowel syndrome is a multifactorial, lower functional gastrointestinal disorder involving disturbances of the brain-gut axis. The pathophysiology provides the basis for pharmacotherapy: abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, intraluminal changes, and mucosal immune activation. Medications targeting chronic constipation or diarrhea may also relieve irritable bowel syndrome. Novel approaches to treatment require approval, and promising agents are guanylate cyclase cagonists, atypical benzodiazepines, antibiotics, immune modulators, and probiotics.

Original languageEnglish (US)
Pages (from-to)481-493
Number of pages13
JournalGastroenterology Clinics of North America
Issue number3
StatePublished - Sep 1 2010


  • Clinical trials
  • Opioids
  • Pharmacodynamics
  • Pharmacology
  • Serotonergics

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Current Medical Treatments of Dyspepsia and Irritable Bowel Syndrome'. Together they form a unique fingerprint.

Cite this